NDA 219873 · Eton
Desmoda
Desmopressin Acetate · Oral
Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 25, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
99
23 Phase 3, 8 recruiting
FAERS reports
2
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 2, 2026.
DESMODA is indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. Limitations of Use • DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus. DESMODA is a vasopressin analog indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. Limitations of Use • DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus.
Mechanism: Desmopressin acetate’s primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine concentration. By influencing the permeability of the renal tubules, V2 receptors help maintain the body’s water balance and overall homeostasis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- DESMODA · DESMOPRESSIN ACETATE 0.05MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Desmopressin" as an intervention, any sponsor and status, largest first.
- A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal EnuresisPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00245479 · 802 participants · Start Apr 2002 · Primary completion Sep 2005
Drug: Primary nocturnal enuresis · For: Nocturnal Enuresis
Sites: Paris, France
- Efficacy and Safety of Desmopressin Melt for the Treatment of NocturiaPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00477490 · 799 participants · Start May 2007 · Primary completion Feb 2008
Drug: desmopressin acetate; Placebo · For: Nocturia
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 80 sites in all
- An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in AdultsPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00615836 · 554 participants · Start Dec 2007 · Primary completion May 2010
Drug: Desmopressin Melt · For: Nocturia
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Anaheim, California · 73 sites in all
- Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese SubjectsPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03051009 · 503 participants · Start Jan 11, 2017 · Primary completion Sep 11, 2018
Drug: Desmopressin ODT 25 μg; Desmopressin ODT 50 μg · For: Nocturia
Sites: Tokyo, Japan
- Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of DesmopressinPivotal-lookingRecruiting
Medical University of BialystokAcademic, hospital or other
NCT05467033 · 424 participants (planned) · Start Sep 1, 2022 · Primary completion Aug 31, 2026
Drug: Desmopressin; intravenous infusion NaCl · For: Kidney Biopsy
Sites: Bialystok, Poland
- Study on Chinese and Western Medicine in MNE ChildrenPivotal-lookingCompleted
Children's Hospital of Fudan UniversityAcademic, hospital or other
NCT03733873 · 400 participants · Start Sep 1, 2018 · Primary completion Jan 30, 2020
Drug: Desmopressin; Suoquan · For: Monosymptomatic Nocturnal Enuresis
Sites: Shanghai, China
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal EnuresisPivotal-lookingCompleted
Menoufia UniversityAcademic, hospital or other
NCT06771128 · 398 participants · Start Nov 1, 2024 · Primary completion Dec 1, 2025
Drug: Ginkgo Biloba oral tablet; Desmopressin Acetate 0.2 mg Tablets and 2 more · For: Nocturnal Enuresis in Children; Desmopressin; Monosymptomatic Nocturnal Enuresis
Sites: Shebin El-Kom, Egypt
- Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male PatientsPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01262456 · 395 participants · Start Feb 2011 · Primary completion Jan 2012
Drug: Desmopressin; Placebo · For: Nocturia
Sites: Anniston, Alabama; Huntsville, Alabama; Scottsdale, Arizona · 56 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anger1
- infantile spasms1
- mood altered1
- off label use1
- suicidal ideation1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Management of nocturnal enuresis in children.
Cammisa I, Zona M, Ferrara P · Minerva Pediatr (Torino) 2025 · Systematic Review
- Central diabetes insipidus (vasopressin deficiency) after surgery for pituitary tumours: a systematic review and meta-analysis.
Fountas A, Coulden A, Fernández-García S, et al. · Eur J Endocrinol 2024 · Systematic Review, Meta-Analysis
- Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's disease.
Peabody CA, Davies H, Berger PA, et al. · Neurobiol Aging 1986 · Clinical Trial, Comparative Study
- Desmopressin for treating nocturia in men.
Han J, Jung JH, Bakker CJ, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Desmopressin for treating nocturia in men.
Han J, Jung JH, Bakker CJ, et al. · BJU Int 2018 · Meta-Analysis, Systematic Review
- Dynamic Testing for Differential Diagnosis of ACTH-Dependent Cushing Syndrome: A Systematic Review and Meta-analysis.
Ceccato F, Barbot M, Mondin A, et al. · J Clin Endocrinol Metab 2023 · Meta-Analysis, Systematic Review
Sponsor: Eton
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.